Hidradenitis suppurativa (HS) is a chronic, follicular occlusive, inflammatory skin condition. It affects the intertriginous skin areas of the axillary, groin, perianal, perineal, and inframammary regions. It presents as recurrent, inflamed nodules and abscesses, draining sinus tracts and bands of severe scar formation. It is associated with pain, bad odor, discharge, and disfigurement. Severity of the disease is staged clinically according to the Hurley staging system. Treatment should include avoidance of trauma to the skin, discontinuation of smoking, and losing weight. The affected region should be washed by antiseptics. In addition, pain should be managed; topical clindamycin cream and topical resorcinol may be applied. Other treatments are intralesional corticosteroid injections and oral tetracyclines. Systemic glucocorticoids, cyclosporine, or the TNF-alpha inhibitors—adalimumab and infliximab—are sometimes tried. In severe cases cold knife or CO2 laser excision of lesions may be used to unroof the lesions, nodules, or sinuses. Wide excision is appropriate for advanced disease. Extensive excisions with skin grafts are also used.
This is a preview of subscription content, log in to check access.
Sellheyer K, Krahl D. “Hidradenitis suppurativa” is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol. 2005;44:535.CrossRefGoogle Scholar
Kouris A, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232:687.CrossRefGoogle Scholar
Garg A, Kirby JS, Lavian J, et al. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153:760.CrossRefGoogle Scholar
von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14:389.CrossRefGoogle Scholar
Faivre C, Villani AP, Aubin F, et al. Hidradenitis suppurativa (HS): an unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases. J Am Acad Dermatol. 2016;74:1153.CrossRefGoogle Scholar
Riis PT, Vinding GR, Ring HC, Jemec GB. Disutility in patients with hidradenitis suppurativa: a cross-sectional study using EuroQoL-5D. Acta Derm Venereol. 2016;96:222.CrossRefGoogle Scholar
Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigk RK, Roenigk HH, editors. Dermatologic surgery. New York: Marcel Dekker; 1989. p. 729.Google Scholar
von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367.CrossRefGoogle Scholar